Cargando…

Free Insulin-like Growth Factor (IGF)-I in Children with PWS

In children with Prader–Willi syndrome (PWS), the standard growth hormone (GH) dose often results in high immunoreactive IGF-I levels. These high immunoreactive IGF-I levels lead to concern because their long-term effects are unknown. As a result, clinicians have to lower the GH dose, which worsens...

Descripción completa

Detalles Bibliográficos
Autores principales: Damen, Layla, Elizabeth, Melitza S. M., Donze, Stephany H., van den Berg, Sjoerd A. A., de Graaff, Laura C. G., Hokken-Koelega, Anita C. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911349/
https://www.ncbi.nlm.nih.gov/pubmed/35268371
http://dx.doi.org/10.3390/jcm11051280
_version_ 1784666778244218880
author Damen, Layla
Elizabeth, Melitza S. M.
Donze, Stephany H.
van den Berg, Sjoerd A. A.
de Graaff, Laura C. G.
Hokken-Koelega, Anita C. S.
author_facet Damen, Layla
Elizabeth, Melitza S. M.
Donze, Stephany H.
van den Berg, Sjoerd A. A.
de Graaff, Laura C. G.
Hokken-Koelega, Anita C. S.
author_sort Damen, Layla
collection PubMed
description In children with Prader–Willi syndrome (PWS), the standard growth hormone (GH) dose often results in high immunoreactive IGF-I levels. These high immunoreactive IGF-I levels lead to concern because their long-term effects are unknown. As a result, clinicians have to lower the GH dose, which worsens body composition and quality of life. As clinical features do not seem to correspond to immunoreactive IGF-I values, it is questionable whether immunoreactive IGF-I is a suitable marker for GH dosing, or whether another parameter better reflects IGF-I bioavailability and bioactivity. We, therefore, investigate serum immunoreactive IGF-I, free IGF-I and IGFBP-3 levels in 70 GH-treated children with PWS. Our study showed that, although immunoreactive IGF-I levels were high (>2 SDS) in the vast majority of prepubertal and pubertal children, free IGF-I SDS levels were <0 SDS in most and <1 SDS in all. Free IGF-I correlated with the immunoreactive IGF-I, IGFBP-3 and IGF-I/IGFBP-3 ratio. We conclude that there is a major discrepancy between immunoreactive and free IGF-I levels. While in the majority of GH-treated children with PWS, immunoreactive IGF-I levels were high, free IGF-I levels were <0 SDS in most. Our data appear to be very reassuring and suggest that free IGF-I levels should also be taken into consideration when the immunoreactive IGF-I levels are >2 SDS in GH-treated children with PWS.
format Online
Article
Text
id pubmed-8911349
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89113492022-03-11 Free Insulin-like Growth Factor (IGF)-I in Children with PWS Damen, Layla Elizabeth, Melitza S. M. Donze, Stephany H. van den Berg, Sjoerd A. A. de Graaff, Laura C. G. Hokken-Koelega, Anita C. S. J Clin Med Article In children with Prader–Willi syndrome (PWS), the standard growth hormone (GH) dose often results in high immunoreactive IGF-I levels. These high immunoreactive IGF-I levels lead to concern because their long-term effects are unknown. As a result, clinicians have to lower the GH dose, which worsens body composition and quality of life. As clinical features do not seem to correspond to immunoreactive IGF-I values, it is questionable whether immunoreactive IGF-I is a suitable marker for GH dosing, or whether another parameter better reflects IGF-I bioavailability and bioactivity. We, therefore, investigate serum immunoreactive IGF-I, free IGF-I and IGFBP-3 levels in 70 GH-treated children with PWS. Our study showed that, although immunoreactive IGF-I levels were high (>2 SDS) in the vast majority of prepubertal and pubertal children, free IGF-I SDS levels were <0 SDS in most and <1 SDS in all. Free IGF-I correlated with the immunoreactive IGF-I, IGFBP-3 and IGF-I/IGFBP-3 ratio. We conclude that there is a major discrepancy between immunoreactive and free IGF-I levels. While in the majority of GH-treated children with PWS, immunoreactive IGF-I levels were high, free IGF-I levels were <0 SDS in most. Our data appear to be very reassuring and suggest that free IGF-I levels should also be taken into consideration when the immunoreactive IGF-I levels are >2 SDS in GH-treated children with PWS. MDPI 2022-02-26 /pmc/articles/PMC8911349/ /pubmed/35268371 http://dx.doi.org/10.3390/jcm11051280 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Damen, Layla
Elizabeth, Melitza S. M.
Donze, Stephany H.
van den Berg, Sjoerd A. A.
de Graaff, Laura C. G.
Hokken-Koelega, Anita C. S.
Free Insulin-like Growth Factor (IGF)-I in Children with PWS
title Free Insulin-like Growth Factor (IGF)-I in Children with PWS
title_full Free Insulin-like Growth Factor (IGF)-I in Children with PWS
title_fullStr Free Insulin-like Growth Factor (IGF)-I in Children with PWS
title_full_unstemmed Free Insulin-like Growth Factor (IGF)-I in Children with PWS
title_short Free Insulin-like Growth Factor (IGF)-I in Children with PWS
title_sort free insulin-like growth factor (igf)-i in children with pws
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911349/
https://www.ncbi.nlm.nih.gov/pubmed/35268371
http://dx.doi.org/10.3390/jcm11051280
work_keys_str_mv AT damenlayla freeinsulinlikegrowthfactorigfiinchildrenwithpws
AT elizabethmelitzasm freeinsulinlikegrowthfactorigfiinchildrenwithpws
AT donzestephanyh freeinsulinlikegrowthfactorigfiinchildrenwithpws
AT vandenbergsjoerdaa freeinsulinlikegrowthfactorigfiinchildrenwithpws
AT degraafflauracg freeinsulinlikegrowthfactorigfiinchildrenwithpws
AT hokkenkoelegaanitacs freeinsulinlikegrowthfactorigfiinchildrenwithpws